Diagnostic Imaging July 16, 2024
Jeff Hall

Offering dedicated PET imaging of the brain, the compact NeuroLF system may facilitate patient comfort while enabling detection and monitoring of brain tumors, epilepsy, and neurodegenerative diseases such as Alzheimer’s disease.

The Food and Drug Administration (FDA) has granted 510(k) clearance for the NeuroLF system, which offers dedicated positron emission tomography (PET) imaging of the brain.

In light of the recent FDA approval of another disease-modifying therapy (Kisunla, Lilly) for Alzheimer’s disease, which reportedly accounts for approximately 70 percent of dementia cases for patients over 60 years of age, the FDA clearance of the NeuroLF system for monitoring and detection of neurological conditions is particularly timely, according to Positrigo, the developer of the NeuroLF device.

Positrigo noted the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: FDA, Govt Agencies, Medical Devices
Related Articles:
STAT+: Trump’s FDA director pick has a history of criticizing the agency. Here are seven examples
Trump names nominees to lead CDC, FDA, and his pick for surgeon general
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
New FDA Panel Weighs In on Regulating Generative AI in Healthcare
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA

Share This Article